33.93
-0.51 (-1.48%)
| Previous Close | 34.44 |
| Open | 34.00 |
| Volume | 1,162,589 |
| Avg. Volume (3M) | 735,868 |
| Market Cap | 1,255,482,496 |
| Price / Earnings (Forward) | 37.31 |
| Price / Sales | 5.86 |
| Price / Book | 31.74 |
| 52 Weeks Range | |
| Earnings Date | 10 Nov 2025 |
| Profit Margin | -10.19% |
| Operating Margin (TTM) | -23.48% |
| Diluted EPS (TTM) | -0.610 |
| Quarterly Revenue Growth (YOY) | 38.30% |
| Total Debt/Equity (MRQ) | 410.02% |
| Current Ratio (MRQ) | 0.910 |
| Operating Cash Flow (TTM) | 2.09 M |
| Levered Free Cash Flow (TTM) | -26.88 M |
| Return on Assets (TTM) | 0.90% |
| Return on Equity (TTM) | -37.31% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Bullish | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Mixed | |
| Stock | Harrow, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 2.88 |
|
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company’s FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company’s ophthalmology-focused pharmaceutical compounding business. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 15.07% |
| % Held by Institutions | 57.11% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| First Turn Management, Llc | 30 Jun 2025 | 228,761 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 74.00 (B. Riley Securities, 118.10%) | Buy |
| Median | 67.50 (98.94%) | |
| Low | 63.00 (BTIG, 85.68%) | Buy |
| Average | 67.67 (99.44%) | |
| Total | 6 Buy | |
| Avg. Price @ Call | 45.15 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Nov 2025 | 69.00 (103.36%) | Buy | 38.44 |
| 29 Sep 2025 | 64.00 (88.62%) | Buy | 48.40 | |
| Ladenburg Thalmann | 12 Nov 2025 | 66.00 (94.52%) | Buy | 38.44 |
| B. Riley Securities | 01 Oct 2025 | 74.00 (118.10%) | Buy | 48.37 |
| 23 Sep 2025 | 70.00 (106.31%) | Buy | 48.85 | |
| BTIG | 29 Sep 2025 | 63.00 (85.68%) | Buy | 48.40 |
| 24 Sep 2025 | 63.00 (85.68%) | Buy | 47.88 | |
| Lake Street | 29 Sep 2025 | 70.00 (106.31%) | Buy | 48.40 |
| Craig-Hallum | 23 Sep 2025 | 64.00 (88.62%) | Buy | 48.85 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 18 Nov 2025 | Announcement | Harrow Announces Closing of Acquisition of Melt Pharmaceuticals |
| 10 Nov 2025 | Announcement | Harrow Announces Third Quarter 2025 Financial Results |
| 27 Oct 2025 | Announcement | Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025 |
| 06 Oct 2025 | Announcement | ImprimisRx Announces Leadership Changes |
| 26 Sep 2025 | Announcement | Harrow to Acquire Melt Pharmaceuticals |
| 25 Sep 2025 | Announcement | Harrow Launches Harrow Access for All (HAFA) |
| 15 Sep 2025 | Announcement | Harrow Announces Agenda and Speakers for Investor & Analyst Day |
| 08 Sep 2025 | Announcement | Harrow Announces Offering of $250.0 Million Senior Unsecured Notes Due 2030 |
| 08 Sep 2025 | Announcement | Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |